The Extraordinary General Shareholders' Meeting of Cellectis (Alternext:
ALCLS) was held on Thursday July 31, 2014 in Paris, at the Group's
headquarters . This meeting had been convened to take a decision on a
planned 25,779,047 euros capital increase through the issuance of
2,786,924 new ordinary shares (corresponding to a total par value of
139,346.20 euros) and the suppression of shareholders' preferential
subscription rights in favor of Pfizer.
This planned acquisition of an approximate 10% stake in the capital of
Cellectis SA by Pfizer is part of the agreements signed on June 18, 2014
between the two companies as part of their global strategic
collaboration in the field of cancer immunotherapy.
This capital increase should allow the company to strengthen its equity
and to continue investing in research and development.
At the end of the Meeting, during which more than 45% of voting rights
were cast, the two resolutions supported by the Board of Directors
received 100% favorable votes. The third resolution, which the Board of
Directors had not supported, was rejected.
The actual capital increase is to take place no later than August 15,
The full results of the vote can be examined on the company's website (www.cellectis.com).
The Extraordinary General Shareholders' Meeting provided an opportunity
for André Choulika, Chairman and Chief Executive Officer, to describe
the agreement signed with Pfizer and to explain the Group's positioning
as a key player in the therapeutics field. He also described the part
played by Cellectis in the revolution in adoptive cancer immunotherapy,
using CAR-bearing T lymphocytes.
André Choulika said: "The strategic agreement reached between Pfizer
and Cellectis sets a new phase in our development and helps speeding up
innovation and development capacities for both companies
synergistically. With this alliance, the aim of Pfizer and Cellectis is
- in the mid-term - to provide cancer patients with effective and
suitable curative therapeutic solutions."
Cellectis is a biopharmaceutical company specializing in oncology. Its
mission is to develop a new generation of treatments for cancer, based
on T-cell engineering. Cellectis has accumulated 14 years' experience in
genome engineering - resting on its flagship tools, TALEN™ and
meganucleases, and on the pioneering Pulse Agile electroporation
technology, in order to create a new generation of immunotherapies to
treat leukemia and solid tumors. The adoptive anticancer immunotherapy
developed by Cellectis is based on the first allogenic T-cells
expressing a chimeric antigenic receptor (CAR) targeting acute and
chronic forms of leukemia. CAR technologies are designed to target the
surface antigens of cancer cells. These treatments reduce and have the
potential to overcome the toxicity associated with current
chemotherapies. Thanks to the application of these pioneering genome
engineering technologies to the life sciences, the Cellectis group is
creating innovative products in many areas that are aimed at a variety
of markets. Cellectis is listed on the Alternext market (code: ALCLS).
To find out more about us, visit our website: www.cellectis.com
Warning note from Cellectis
This press release and the information it contains do not constitute an
offer to sell or subscribe to, nor does it solicit offers to purchase or
subscribe to, the shares of Cellectis in any country. This press release
contains forward-looking statements that reflect the objectives of the
company and which are based on current assessments and expectations of
the directors of the company.
[ Back To NFVZone's Homepage ]